MedImmune
E108402
MedImmune is a biotechnology company best known as the biologics research and development arm of AstraZeneca, focusing on innovative therapies such as vaccines and monoclonal antibodies.
All labels observed (2)
| Label | Occurrences |
|---|---|
| MedImmune canonical | 4 |
| MedImmune, LLC | 1 |
How this entity was disambiguated
This entity first appeared as the object of triple T916703 — resolving that mention is where its identity was fixed. The disambiguator weighed these candidate entities and picked the highlighted one (or “None”, minting a new entity). This is how homonymy is resolved: the same surface form can point to different entities.
NED1
Entity disambiguation (via context triple)
gpt-5-mini-2025-08-07
Target entity: MedImmune Context triple: [Granta Park, hasTenant, MedImmune]
-
A.
Genentech
Genentech is a pioneering American biotechnology company known for developing groundbreaking therapies and being one of the first firms to apply genetic engineering to medicine.
-
B.
Biogen
Biogen is a major American biotechnology company known for developing therapies for neurological and neurodegenerative diseases.
-
C.
GlaxoSmithKline
GlaxoSmithKline is a global biopharmaceutical company known for developing and manufacturing prescription medicines, vaccines, and consumer healthcare products.
-
D.
Merck & Co.
Merck & Co. is a major American pharmaceutical company known for developing and producing vaccines, oncology drugs, and other innovative medicines.
-
E.
Roche
Roche is a major Swiss multinational healthcare company and one of the world’s leading pharmaceutical and diagnostics firms.
- F. None of above. chosen
- G. Unsure - the case is ambiguous/there is not enough information to decide.
NED2
Entity disambiguation (via description)
gpt-5-mini-2025-08-07
Target entity: MedImmune Target entity description: MedImmune is a biotechnology company best known as the biologics research and development arm of AstraZeneca, focusing on innovative therapies such as vaccines and monoclonal antibodies.
-
A.
Genentech
Genentech is a pioneering American biotechnology company known for developing groundbreaking therapies and being one of the first firms to apply genetic engineering to medicine.
-
B.
Biogen
Biogen is a major American biotechnology company known for developing therapies for neurological and neurodegenerative diseases.
-
C.
GlaxoSmithKline
GlaxoSmithKline is a global biopharmaceutical company known for developing and manufacturing prescription medicines, vaccines, and consumer healthcare products.
-
D.
Merck & Co.
Merck & Co. is a major American pharmaceutical company known for developing and producing vaccines, oncology drugs, and other innovative medicines.
-
E.
Roche
Roche is a major Swiss multinational healthcare company and one of the world’s leading pharmaceutical and diagnostics firms.
- F. None of above. chosen
Statements (47)
| Predicate | Object |
|---|---|
| instanceOf |
biopharmaceutical company
ⓘ
biotechnology company ⓘ |
| acquiredBy | AstraZeneca ⓘ |
| acquisitionType | wholly owned subsidiary ⓘ |
| acquisitionYear | 2007 ⓘ |
| alternativeName |
MedImmune, LLC
ⓘ
linked to:
MedImmune
|
| collaboratesWith |
academic research institutions
ⓘ
biotechnology companies ⓘ pharmaceutical companies ⓘ |
| country |
United States
ⓘ
linked to:
United States of America
|
| developed | Synagis ⓘ |
| focusesOn |
biologics research and development
ⓘ
innovative therapies ⓘ monoclonal antibodies ⓘ vaccines ⓘ |
| foundedBy | Wayne T. Hockmeyer NERFINISHED ⓘ |
| hasResearchCenterIn |
Cambridge, United Kingdom
ⓘ
linked to:
Cambridge, England
Gaithersburg, Maryland ⓘ
linked to:
Gaithersburg
Mountain View, California ⓘ
linked to:
Mountain View, California, United States
|
| headquartersCountry |
United States
ⓘ
linked to:
United States of America
|
| headquartersLocation |
Gaithersburg, Maryland
ⓘ
linked to:
Gaithersburg
|
| industry |
biotechnology
ⓘ
pharmaceuticals ⓘ |
| notableProduct | Synagis ⓘ |
| operatesAs | biologics R&D unit of AstraZeneca ⓘ |
| parentCompany | AstraZeneca ⓘ |
| researchArea |
autoimmune diseases
ⓘ
inflammatory diseases ⓘ influenza vaccines ⓘ oncology immunotherapies ⓘ respiratory syncytial virus (RSV) ⓘ |
| roleWithinParent | biologics research and development arm of AstraZeneca ⓘ |
| specializesIn |
autoimmune and inflammatory disease biologics
ⓘ
infectious disease therapies ⓘ oncology biologics ⓘ respiratory disease therapies ⓘ |
| subsidiaryOf | AstraZeneca ⓘ |
| SynagisIndication | prevention of serious lower respiratory tract disease caused by respiratory syncytial virus (RSV) in high-risk pediatric patients ⓘ |
| technologyPlatform |
monoclonal antibody technology
ⓘ
vaccine technology ⓘ |
| therapeuticArea |
autoimmune and inflammatory diseases
ⓘ
infectious diseases ⓘ oncology ⓘ respiratory diseases ⓘ |
| therapeuticModality |
monoclonal antibodies
ⓘ
recombinant proteins ⓘ vaccines ⓘ |
How these facts were elicited
The pipeline generated the facts above by prompting gpt-5.1 with this entity's name + description and the instruction below.
Instruction
You are a knowledge base construction expert. Given a subject entity and a description of it, return factual statements that you know for the subject as a JSON list of dictionaries(triples), where keys must be "subject", "predicate" and "object". The number of facts may be very high, between 25 to 50 or more, for very popular subjects. For less popular subjects, the number of facts can be very low, like 5 or 10. # Requirements - If you don't know the subject at all, return an empty list. - If the subject is not a named entity, return an empty list. - Include at least one triple where predicate is "instanceOf". - Do not get too wordy. - Separate several objects into multiple triples with one object.
Input
Subject: MedImmune Description of subject: MedImmune is a biotechnology company best known as the biologics research and development arm of AstraZeneca, focusing on innovative therapies such as vaccines and monoclonal antibodies.
Referenced by (5)
Full triples — surface form annotated when it differs from this entity's canonical label.
linked to: MedImmune